Kolexia
Gazzah Anas
Oncologie médicale
Gustave-Roussy
Villejuif, France
227 Activités
42 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du poumon Carcinome pulmonaire non à petites cellules Carcinome pulmonaire à petites cellules Adénocarcinome Carcinomes Métastase tumorale Adénocarcinome pulmonaire Récidive tumorale locale Mélanome

Industries

A+A
4 collaboration(s)
Dernière en 2023
Kantar Health
4 collaboration(s)
Dernière en 2022
Pfizer
4 collaboration(s)
Dernière en 2023
CERNER ENVIZA FRANCE SAS
2 collaboration(s)
Dernière en 2023

Dernières activités

Evaluation of SAR408701 in Patients With Advanced Solid Tumors: A First-in-Human Study for the Evaluation of the Safety, Pharmacokinetics and Antitumor Activity of SAR408701 in Patients With Advanced Solid Tumors
Essai Clinique (Sanofi)   07 février 2024
KontRASt-01 Update: Safety and Efficacy of JDQ443 in KRAS G12C-Mutated Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)
International journal of radiation oncology, biology, physics   01 janvier 2024
Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial.
British journal of cancer   14 décembre 2023
Impact thérapeutique du profilage moléculaire des patients atteints de mélanome résistant au traitement standard : résultats « en vie réelle »
Journées dermatologiques de Paris 2023   01 décembre 2023
Antibody drug conjugates in older patients: State of the art.
Critical reviews in oncology/hematology   24 novembre 2023
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma: A Phase Ib, Open-label, Multicenter Study of Oral LXH254-centric Combinations in Adult Patients With Advanced or Metastatic KRAS or BRAF Mutant Non-Small Cell Lung Cancer or NRAS Mutant Melanoma
Essai Clinique (Novartis)   09 novembre 2023
1659P The use of liquid biopsy in patients with advanced pancreatic cancer (PDAC) to guide enrollment in phase I clinical trials
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
80P Tumor microenvironment (TME) defines prognosis of EGFR-mutant non-small cell lung cancer (NSCLC)
Molecular Analysis for Precision Oncology Congress 2023 4-6 October 2023   01 octobre 2023
1161P Therapeutic outcome of molecular profiling of melanoma patients resistant to standard treatment: Real-world data
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
1845P Exclusion of patients with psychiatric disorders from early phase oncology trials: A limited access to innovation?
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023